Cristian Pedreros-Rosales

Dr. Cristian Pedreros-Rosales

Internal Medicine, Universidad de Concepción, Concepción, Biobío, Chile
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2023 in Toxins
Verified
Journal Article
Open access
PDF file
CPCristian Pedreros-Rosales
Cristian Pedreros-Rosales
AJAquiles Jara
Aquiles Jara
ELeduardo lorca
eduardo lorca
SMSergio Mezzano
Sergio Mezzano
RPRoberto Pécoits-Filho
Roberto Pécoits-Filho
PHPatricia Herrera
Patricia Herrera
Dialysis treatment has improved the survival of patients with kidney failure. However, the hospitalization and mortality rates remain alarmingly high, primarily due to incomplete uremic toxin elimination. High-volume hemodiafiltration (HDF) has emerged as a promising approach that significantly improves patient outcomes by effectively eliminating medium and large uremic toxins, which explains its increasing adoption, particularly in Europe and Japan. Interest in this therapy has grown following the findings of the recently published CONVINCE study, as well as the need to understand the mechanisms behind the benefits. This comprehensive review aims to enhance the scientific understanding by explaining the underlying physiological mechanisms that contribute to the positive effects of HDF in terms of short-term benefits, like hemodynamic tolerance and cardiovascular disease. Additionally, it explores the rationale behind the medium-term clinical benefits, including phosphorus removal, the modulation of inflammation and oxidative stress, anemia management, immune response modulation, nutritional effects, the mitigation of bone disorders, neuropathy relief, and amyloidosis reduction. This review also analyzes the impact of HDF on patient-reported outcomes and mortality. Considering the importance of applying personalized uremic toxin removal strategies tailored to the unique needs of each patient, high-volume HDF appears to be the most effective treatment to date for patients with renal failure. This justifies the need to prioritize its application in clinical practice, initially focusing on the groups with the greatest potential benefits and subsequently extending its use to a larger number of patients.

17 April 2007 in Transplantation Proceedings
Verified
Journal Article
Closed access
HMH. Muller
H. Muller
SSS. Solari
S. Solari
CZC. Zuniga
C. Zuniga
IGI. Guerra
I. Guerra
JTJ. Troncoso
J. Troncoso
CPCristian Pedreros-Rosales
Cristian Pedreros-Rosales

29 April 2008 in Transplantation Proceedings
Verified
Journal Article
Closed access
HMH. Müller
H. Müller
SSS. Solari
S. Solari
CZC. Zuñiga
C. Zuñiga
CPCristian Pedreros-Rosales
Cristian Pedreros-Rosales
JTJ. Troncoso
J. Troncoso
EAE. Albornoz
E. Albornoz

1 November 2019 in Revista médica de Chile
Verified
Journal Article
Open access
PDF file
HMHans Müller-Ortiz
Hans Müller-Ortiz
CPCristian Pedreros-Rosales
Cristian Pedreros-Rosales
AVAldo Vera-Calzaretta
Aldo Vera-Calzaretta
AGAlexis González-Burboa
Alexis González-Burboa
CMCarlos Zúñiga-San Martín
Carlos Zúñiga-San Martín
MOMaría Soledad Oliveros-Romero
María Soledad Oliveros-Romero
Chronic kidney disease is associated with an increase in cardiovascular risk and mortality, and a decrease in the health-related quality of life. It is known that the physical capacity of patients with chronic kidney disease is lower than their healthy counterparts. It also decreases progressively after the start of hemodialysis, even leading to the loss of functional independence. There is a positive association between exercise and improvement of many targets in chronic kidney disease, especially in dialysis patients, such as cellular apoptosis, immune improvement and inflammation. In addition, several clinical studies and systematic reviews show an improvement in different clinical and laboratory variables and suggest a lower mortality, proving a reduction of health care economic costs. Exercise intervention in dialysis is safe. Although different guidelines promote exercise, it is necessary to work on its implementation on a large scale.

1 May 2022 in Revista Clínica Española
Verified
Journal Article
Closed access
GRG. Ramírez-Guerrero
G. Ramírez-Guerrero
HMH. Müller-Ortiz
H. Müller-Ortiz
CPCristian Pedreros-Rosales
Cristian Pedreros-Rosales

1 November 2019 in Revista médica de Chile
Verified
Journal Article
Open access
PDF file
AGAlexis González-Burboa
Alexis González-Burboa
CCCarlos Acevedo Cossio
Carlos Acevedo Cossio
AVAldo Vera-Calzaretta
Aldo Vera-Calzaretta
PVPatricia Villaseca-Silva
Patricia Villaseca-Silva
HMHans Müller-Ortiz
Hans Müller-Ortiz
ÁPÁngel Otero Puime
Ángel Otero Puime
Chile, en lo que respecta al grupo de personas entre 20 a 79 años, se sitúa en el segundo lugar de Latinoamérica 1 . Según datos disponibles 3 la prevalencia de diabetes en la población chilena es de 9,4% en población mayor a 15 años, de los cuales, 52,1% recibe algún tratamiento farmacológico o no farmacológico.